Invest in Israel Newsletter March 2010 Edition
VC Cafe
APRIL 8, 2010
Through the acquisition of Ratiopharm, which is the second-largest player in the German generics market, Europe’s biggest, Israel’s Teva becomes number one in Europe as its presence in Spain, Italy and France is also boosted. Tags: Invest in Israel OSS OTC CRM. The deal is expected to capture significant synergies for Teva.
68 
Let's personalize your content